152 related articles for article (PubMed ID: 38275831)
21. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.
Giannini EG; Moscatelli A; Pellegatta G; Vitale A; Farinati F; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Baroni GS; Virdone R; Masotto A; Trevisani F; ;
Am J Gastroenterol; 2016 Jan; 111(1):70-7. PubMed ID: 26729544
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of alpha-fetoprotein staging system for hepatocellular carcinoma in noncirrhotic patients.
Burnett NP; Dunki-Jacobs EM; Callender GG; Anderson RJ; Scoggins CR; McMasters KM; Martin RC
Am Surg; 2013 Jul; 79(7):716-22. PubMed ID: 23816006
[TBL] [Abstract][Full Text] [Related]
23. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C.
Kim YJ; Jung J; Joo JH; Kim SY; Kim JH; Lim YS; Lee HC; Kim JH; Yoon SM
Radiother Oncol; 2019 Dec; 141():95-100. PubMed ID: 31506181
[TBL] [Abstract][Full Text] [Related]
24. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Biolato M; Gallusi G; Iavarone M; Cabibbo G; Racco S; De Santis A; Corte CD; Maida M; Attili AF; Sangiovanni A; Cammà C; La Torre G; Gasbarrini A; Grieco A
Ann Hepatol; 2018; 17(1):110-118. PubMed ID: 29311396
[TBL] [Abstract][Full Text] [Related]
25. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems.
Zhang XF; Qi X; Meng B; Liu C; Yu L; Wang B; Lv Y
Eur J Surg Oncol; 2010 Aug; 36(8):718-24. PubMed ID: 20538423
[TBL] [Abstract][Full Text] [Related]
26. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
27. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.
Liu C; Xiao GQ; Yan LN; Li B; Jiang L; Wen TF; Wang WT; Xu MQ; Yang JY
World J Gastroenterol; 2013 Mar; 19(11):1811-9. PubMed ID: 23555170
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
Adhoute X; Pénaranda G; Raoul JL; Blanc JF; Edeline J; Conroy G; Perrier H; Pol B; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Bronowicki JP; Bourlière M
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):433-40. PubMed ID: 26695429
[TBL] [Abstract][Full Text] [Related]
29. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.
Lin CW; Chen YS; Lo GH; Wu TC; Yeh JH; Yeh ML; Dai CY; Huang JF; Chuang WL; Roberts L; Jun DW; Toyoda H; Yasuda S; Nguyen MH; Yu ML
Hepatol Int; 2021 Aug; 15(4):946-956. PubMed ID: 34008091
[TBL] [Abstract][Full Text] [Related]
30. Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.
Saeki I; Yamasaki T; Yamauchi Y; Kawaoka T; Uchikawa S; Hiramatsu A; Aikata H; Kobayashi K; Kondo T; Ogasawara S; Chiba T; Kawano R; Chayama K; Kato N; Takami T
Cancer Med; 2023 May; 12(9):10625-10635. PubMed ID: 36951579
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
32. Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.
Ge J; Zhang X; Zhang B; Zhu L; Zhao M; Gao W; Chen D
Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101573. PubMed ID: 33281070
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Ilikhan SU; Bilici M; Sahin H; Akca AS; Can M; Oz II; Guven B; Buyukuysal MC; Ustundag Y
World J Gastroenterol; 2015 Jun; 21(22):6999-7007. PubMed ID: 26078578
[TBL] [Abstract][Full Text] [Related]
34. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909
[TBL] [Abstract][Full Text] [Related]
35. The GALAD score and the BALAD-2 score correlate with transarterial and systemic treatment response and survival in patients with hepatocellular carcinoma.
Olbrich A; Niemeyer J; Seiffert H; Ebel S; Gros O; Lordick F; Forstmeyer D; Seehofer D; Rademacher S; Denecke T; Matz-Soja M; Berg T; van Bömmel F
J Cancer Res Clin Oncol; 2024 Feb; 150(2):81. PubMed ID: 38319485
[TBL] [Abstract][Full Text] [Related]
36. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis.
Ha Y; Shim JH; Kim SO; Kim KM; Lim YS; Lee HC
J Gastroenterol Hepatol; 2014 Apr; 29(4):787-93. PubMed ID: 24224567
[TBL] [Abstract][Full Text] [Related]
37. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
38. Evolution and current status of the subclassification of intermediate hepatocellular carcinoma.
Yi PS; Wang H; Li JS
World J Gastrointest Surg; 2020 Mar; 12(3):85-92. PubMed ID: 32218891
[TBL] [Abstract][Full Text] [Related]
39. BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.
Longo L; Rodrigues de Freitas LB; Santos D; Grivicich I; Álvares-da-Silva MR
Am J Clin Oncol; 2019 May; 42(5):466-471. PubMed ID: 30913090
[TBL] [Abstract][Full Text] [Related]
40. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
